UNSPSC 51161549: Nestifylline

This classification denotes a phosphodiesterase inhibitor and bronchodilator with the molecular formula C11H14N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 52915ASM3D, chemically known as 3,7-dihydro-1,3-dimethyl-7-(1,3-dithiolan-2-ylmethyl)-1h-purine-2,6-dione but generally known as nestifylline, which bears US NIH Compound Identifier 65931. European Medicines Agency schedules Nestifylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09209MIG.

UNSPSC 51161549 Nestifylline, a Commodity code, encompasses pharmaceutical supply arrangements for state and local government entities purchasing generic multi-source medications and over-the-counter products through cooperative purchasing vehicles. State and local agencies procure these products via established wholesaler networks to supply healthcare facilities, clinics, and departments requiring pharmaceutical inventories at negotiated pricing. The issuing bodies include state agencies and their cooperative purchasing alliances, which aggregate demand across multiple participating jurisdictions to achieve volume discounts and standardized supply agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, exemplifies the institutional buyers active under this code, extending purchasing access to participating state and local government facilities across member states including Oregon.

The geographic spread under this code reflects multistate cooperative purchasing arrangements centered in the Upper Midwest and Pacific Northwest. The most recent representative opportunity is MMCAP's RFP S1070000015802, posted January 20, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products for award by May 15, 2026, with contract effectiveness on July 1, 2026. Vendors must certify Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), and submit detailed product specifications including National Drug Codes, SKUs, UPCs, strength, dosage form, and manufacturing location. Evaluation weighs price competitiveness at 75 percent, with secondary criteria addressing administrative compliance, EDI capability, and fixed-pricing structures. The contract term runs two years for new vendors, with optional extensions, and incumbents' agreements extend through June 30, 2028. Proposals were due March 26, 2026, with a question cutoff of February 18, 2026.